SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Rantapää Dahlqvist Solbritt) "

Sökning: WFRF:(Rantapää Dahlqvist Solbritt)

  • Resultat 41-50 av 402
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
41.
  • Askling, J, et al. (författare)
  • Haematopoietic malignancies in rheumatoid arthritis : lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
  • 2005
  • Ingår i: Annals of the Rheumatic Diseases. - : BMJ. - 0003-4967 .- 1468-2060. ; 64:10, s. 1414-1420
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND:Patients with rheumatoid arthritis (RA) are at increased risk of malignant lymphomas, and maybe also of leukaemia and multiple myeloma. The effect of tumour necrosis factor (TNF) antagonists on lymphoma risk and characteristics is unclear.OBJECTIVE:To assess expected rates and relative risks of haematopoietic malignancies, especially those associated with TNF antagonists, in large population based cohorts of patients with RA.METHODS:A population based cohort study was performed of patients with RA (one prevalent cohort (n = 53,067), one incident cohort (n = 3703), and one TNF antagonist treated cohort 1999 through 2003 (n = 4160)), who were linked with the Swedish Cancer Register. Additionally, the lymphoma specimens for the 12 lymphomas occurring in patients with RA exposed to TNF antagonists in Sweden 1999 through 2004 were reviewed.RESULTS:Study of almost 500 observed haematopoietic malignancies showed that prevalent and incident patients with RA were at increased risk of lymphoma (SIR = 1.9 and 2.0, respectively) and leukaemia (SIR = 2.1 and 2.2, respectively) but not of myeloma. Patients with RA treated with TNF antagonists had a tripled lymphoma risk (SIR = 2.9) compared with the general population. After adjustment for sex, age, and disease duration, the lymphoma risk after exposure to TNF antagonists was no higher than in the other RA cohorts. Lymphomas associated with TNF antagonists had characteristics similar to those of other RA lymphomas.CONCLUSION:Overall, patients with RA are at equally increased risks for lymphomas and leukaemias. Patients with RA treated with TNF antagonists did not have higher lymphoma risks than other patients with RA. Prolonged observation is needed to determine the long term effects of TNF antagonists on lymphoma risk.
  •  
42.
  • Askling, Johan, et al. (författare)
  • Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden
  • 2005
  • Ingår i: Arthritis and Rheumatism. - : Wiley. - 0004-3591 .- 1529-0131. ; 52:7, s. 1986-1992
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE:Because treatment with tumor necrosis factor (TNF) antagonists may increase the risk of tuberculosis (TB), and because knowledge of the risk of TB in rheumatoid arthritis (RA) not treated with biologics is scarce and of uncertain generalizability to low-risk populations, this study sought to determine the risk of TB among Swedish patients with RA.METHODS:Using data from Swedish nationwide and population-based registers and data from an ongoing monitoring program of TNF antagonists, the relative risks of TB in patients with RA (versus the general population) and of TB associated with TNF antagonists (versus RA patients not treated with biologics) were determined by comparing the incidence of hospitalization for TB in 3 RA cohorts and 2 general population cohorts from 1999 to 2001. We also reviewed the characteristics of all reported cases of TB in RA patients treated with TNF antagonists in Sweden and calculated the incidence of TB per type of TNF antagonist between 1999 and 2004.RESULTS:During 1999-2001, RA patients who were not treated with TNF antagonists were at increased risk of TB versus the general population (relative risk 2.0, 95% confidence interval [95% CI] 1.2-3.4). RA patients treated with TNF antagonists had a 4-fold increased risk of TB (relative risk 4.0, 95% CI 1.3-12) versus RA patients not treated with TNF antagonists. The reported TB cases during 1999-2004 in RA patients exposed to TNF antagonists (9 infliximab, 4 etanercept, 2 both) were predominantly pulmonary. TB occurred up to 3 years following the start of treatment.CONCLUSION:Irrespective of whether TNF antagonists are administered, Swedish patients with RA are at increased risk of TB. During 1999-2001, TNF antagonists were associated with an increased risk of TB, up to 4-fold in magnitude. This increased risk may persist over time during treatment and is related to both infliximab and etanercept.
  •  
43.
  •  
44.
  •  
45.
  •  
46.
  • Askling, Johan, et al. (författare)
  • Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists
  • 2007
  • Ingår i: Annals of the Rheumatic Diseases. - : BMJ. - 0003-4967 .- 1468-2060. ; 66:10, s. 1339-1344
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVES:The degree to which treatment with tumour necrosis factor (TNF) antagonists may be associated with increased risks for serious infections is unclear. An observational cohort study was performed using prospectively collected data from the Swedish Biologics Register (ARTIS) and other national Swedish registers.METHODS:First, in the ARTIS, all 4167 rheumatoid arthritis (RA) patients starting TNF antagonist treatment between 1999 and 2003 were identified. Secondly, in the Swedish Inpatient Register, all individuals hospitalised for any reason and who also carried a diagnosis of RA, between 1964 and 2003 (n = 44 946 of whom 2692 also occurred in ARTIS), were identified. Thirdly, in the Swedish Inpatient Register, all hospitalisations listing an infection between 1999 and 2003 were identified. By cross-referencing these three data sets, RRs for hospitalisation with infection associated with TNF antagonist treatment were calculated within the cohort of 44 946 RA patients, using Cox regression taking sex, age, geography, co-morbidity and use of inpatient care into account.RESULTS:Among the 4167 patients treated with TNF antagonists, 367 hospitalisations with infections occurred during 7776 person-years. Within the cohort of 44 496 RA patients, the RR for infection associated with TNF antagonists was 1.43 (95% CI 1.18 to 1.73) during the first year of treatment, 1.15 (95% CI 0.88 to 1.51) during the second year of treatment, and 0.82 (95% CI 0.62 to 1.08) for subjects remaining on their first TNF antagonist treatment after 2 years.CONCLUSION:Treatment with TNF antagonists may be associated with a small to moderate increase in risk of hospitalisation with infection, which disappears with increasing treatment duration.
  •  
47.
  •  
48.
  •  
49.
  •  
50.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 41-50 av 402
Typ av publikation
tidskriftsartikel (357)
annan publikation (15)
doktorsavhandling (15)
konferensbidrag (6)
forskningsöversikt (6)
bokkapitel (3)
visa fler...
visa färre...
Typ av innehåll
refereegranskat (310)
övrigt vetenskapligt/konstnärligt (90)
populärvet., debatt m.m. (2)
Författare/redaktör
Rantapää-Dahlqvist, ... (292)
Dahlqvist, Solbritt ... (61)
Klareskog, Lars (40)
Rönnblom, Lars (37)
Brink, Mikael (34)
Gunnarsson, Iva (30)
visa fler...
Jönsen, Andreas (28)
Kokkonen, Heidi (28)
Svenungsson, Elisabe ... (27)
Sandling, Johanna K. (27)
Ärlestig, Lisbeth (24)
Rantapää-Dahlqvist, ... (23)
Padyukov, Leonid (22)
KLARESKOG, L (21)
Wållberg Jonsson, So ... (21)
Johansson, Linda (21)
Eloranta, Maija-Leen ... (19)
Sjöwall, Christopher (19)
Ljung, Lotta (18)
Berglin, Ewa, MD, Ph ... (18)
Leonard, Dag, 1975- (17)
Bengtsson, Anders A. (17)
Nordmark, Gunnel (16)
Rönnelid, Johan (16)
Askling, Johan (16)
Johansson, Ingegerd (15)
Bengtsson, Christine (15)
Wållberg-Jonsson, So ... (15)
Gregersen, Peter K. (14)
Bengtsson, Anders (13)
Lindblad-Toh, Kersti ... (13)
Alenius, Gerd-Marie (13)
Syvänen, Ann-Christi ... (13)
Askling, J (13)
Jacobsson, Lennart (13)
Rantapää-Dahlqvist, ... (13)
Sturfelt, Gunnar (12)
Alfredsson, Lars (12)
Eriksson, Catharina, ... (12)
Berglin, Ewa (12)
Huizinga, Tom W. J. (12)
Rantapää-Dahlqvist, ... (12)
Lindblad, S (11)
Lysholm, J (11)
Syvänen, Ann-Christi ... (11)
Bertilsson, L (11)
Feltelius, N (11)
Worthington, Jane (11)
Kastbom, Alf (11)
Bianchi, Matteo (11)
visa färre...
Lärosäte
Umeå universitet (384)
Karolinska Institutet (58)
Uppsala universitet (55)
Lunds universitet (25)
Göteborgs universitet (15)
Linköpings universitet (10)
visa fler...
Örebro universitet (2)
Linnéuniversitetet (2)
Sveriges Lantbruksuniversitet (2)
Chalmers tekniska högskola (1)
visa färre...
Språk
Engelska (395)
Svenska (7)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (281)
Naturvetenskap (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy